Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

310 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Amsacrine combined with etoposide and methylprednisolone is a feasible and safe component in first-line intensified treatment of pediatric patients with high-risk acute lymphoblastic leukemia in CoALL08-09 trial.
Mezger K, Ebert S, Muhle HE, Stadt UZ, Borkhardt A, Dilloo D, Faber J, Feuchtinger T, Imschweiler T, Jorch N, Pekrun A, Schmid I, Schramm F, Zimmermann M, Horstmann MA, Escherich G. Mezger K, et al. Among authors: schmid i. Pediatr Blood Cancer. 2022 Dec;69(12):e29997. doi: 10.1002/pbc.29997. Epub 2022 Sep 21. Pediatr Blood Cancer. 2022. PMID: 36129234
First experience of the AML-Berlin-Frankfurt-Münster group in pediatric patients with standard-risk acute promyelocytic leukemia treated with arsenic trioxide and all-trans retinoid acid.
Creutzig U, Dworzak MN, Bochennek K, Faber J, Flotho C, Graf N, Kontny U, Rossig C, Schmid I, von Stackelberg A, Mueller JE, von Neuhoff C, Reinhardt D, von Neuhoff N. Creutzig U, et al. Among authors: schmid i. Pediatr Blood Cancer. 2017 Aug;64(8). doi: 10.1002/pbc.26461. Epub 2017 Jan 23. Pediatr Blood Cancer. 2017. PMID: 28111878
MRD response in a refractory paediatric T-ALL patient through anti-programmed cell death 1 (PD-1) Ab treatment associated with induction of fatal GvHD.
Boekstegers AM, Blaeschke F, Schmid I, Wiebking V, Immler S, Hoffmann F, Bochmann K, Müller S, Grünewald TGP, Feucht J, Feuchtinger T. Boekstegers AM, et al. Among authors: schmid i. Bone Marrow Transplant. 2017 Aug;52(8):1221-1224. doi: 10.1038/bmt.2017.107. Epub 2017 Jun 5. Bone Marrow Transplant. 2017. PMID: 28581460 No abstract available.
Daunorubicin during delayed intensification decreases the incidence of infectious complications - a randomized comparison in trial CoALL 08-09.
Schramm F, Zimmermann M, Jorch N, Pekrun A, Borkhardt A, Imschweiler T, Christiansen H, Faber J, Feuchtinger T, Schmid I, Beron G, Horstmann MA, Escherich G. Schramm F, et al. Among authors: schmid i. Leuk Lymphoma. 2019 Jan;60(1):60-68. doi: 10.1080/10428194.2018.1473575. Epub 2018 Jul 3. Leuk Lymphoma. 2019. PMID: 29966458 Clinical Trial.
Newly Diagnosed Metastatic Intracranial Ependymoma in Children: Frequency, Molecular Characteristics, Treatment, and Outcome in the Prospective HIT Series.
Benesch M, Mynarek M, Witt H, Warmuth-Metz M, Pietsch T, Bison B, Pfister SM, Pajtler KW, Kool M, Schüller U, Pietschmann K, Juhnke BO, Tippelt S, Fleischhack G, Schmid I, Kramm CM, Vorwerk P, Beilken A, Classen CF, Hernáiz Driever P, Kropshofer G, Imschweiler T, Lemmer A, Kortmann RD, Rutkowski S, von Hoff K. Benesch M, et al. Among authors: schmid i. Oncologist. 2019 Sep;24(9):e921-e929. doi: 10.1634/theoncologist.2018-0489. Epub 2019 Mar 8. Oncologist. 2019. PMID: 30850560 Free PMC article. Clinical Trial.
310 results